PT  - JOURNAL ARTICLE
AU  - Hersch, S. M.
AU  - Gevorkian, S.
AU  - Marder, K.
AU  - Moskowitz, C.
AU  - Feigin, A.
AU  - Cox, M.
AU  - Como, P.
AU  - Zimmerman, C.
AU  - Lin, M.
AU  - Zhang, L.
AU  - Ulug, A. M.
AU  - Beal, M. F.
AU  - Matson, W.
AU  - Bogdanov, M.
AU  - Ebbel, E.
AU  - Zaleta, A.
AU  - Kaneko, Y.
AU  - Jenkins, B.
AU  - Hevelone, N.
AU  - Zhang, H.
AU  - Yu, H.
AU  - Schoenfeld, D.
AU  - Ferrante, R.
AU  - Rosas, H. D.
TI  - Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
AID  - 10.1212/01.wnl.0000194318.74946.b6
DP  - 2006 Jan 24
TA  - Neurology
PG  - 250--252
VI  - 66
IP  - 2
4099  - http://n.neurology.org/content/66/2/250.short
4100  - http://n.neurology.org/content/66/2/250.full
SO  - Neurology2006 Jan 24; 66
AB  - In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2′-deoxyguanosine (8OH2′dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.